Compare Ginkgo Bioworks Holdings Inc (DNA) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs VICI Properties Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M), while VICI Properties Inc trades at $26.03 (market cap $28.71B). The key difference: VICI Properties Inc is far larger — about 55.7× Ginkgo Bioworks Holdings Inc's market cap, and VICI Properties Inc pays a 6.9% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | VICI | |
|---|---|---|
Market Cap | $515.15M | $28.71B |
Sector | Health | Real Estate |
52-Week High | $16.14 | $33.78 |
52-Week Low | $5.48 | $25.94 |
Enterprise Value | $617.10M | $46.26B |
Dividend Yield | — | 6.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.
DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.
VICI Properties trades at $26.74, up 0.66% today, with a neutral technical signal and strong fundamentals including a 67.5% net income margin and a P/E of 10.1. Recent Q2 2026 earnings showed an EPS miss but revenue beat, while the company raised its full-year AFFO guidance. A $1.75 billion note offering in August 2026 supports capital deployment.
The outlook remains positive with a 76.9% analyst buy rating and a $29.83 consensus price target, offering potential upside. Risks include earnings volatility and high debt, but the near 7% dividend yield and stable cash flows provide investor appeal in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
